Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.67 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.66 |
| ▸ | CA5A | P35218 | 1/20 | 0.66 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.64 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.63 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.63 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.63 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.63 |
| ▸ | NT5E | P21589 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316711 | 0.93 | ADORA3 (0.75) | P2RX3ADORA3ADORA1P2RY12CA5A | |
| SCHEMBL3810246 | 0.88 | P2RX3 (0.87) | P2RX3P2RY12CA5AP2RY1ENPP1 | |
| SCHEMBL3319754 | 0.88 | P2RX3 (0.87) | P2RX3P2RY12CA5AP2RY1ENPP1 | |
| SCHEMBL6514561 | 0.88 | P2RX3 (1.00) | P2RX3ADORA3P2RY12P2RY1ENPP1 | |
| SCHEMBL6514575 | 0.88 | P2RX3 (1.00) | P2RX3ADORA3P2RY12P2RY1ENPP1 | |
| SCHEMBL29614811 | 0.88 | P2RX3 (1.00) | P2RX3ADORA3P2RY12P2RY1ENPP1 | |
| SCHEMBL8862400 | 0.87 | P2RX3 (0.94) | P2RX3ADORA3P2RY12CA5AP2RY1 | |
| SCHEMBL8862431 | 0.86 | P2RX3 (0.81) | P2RX3ADORA1P2RY12CA5AP2RY1 | |
| SCHEMBL8862414 | 0.86 | P2RX3 (0.98) | P2RX3ADORA3P2RY12CA5AP2RY1 | |
| SCHEMBL3318460 | 0.85 | P2RX3 (1.00) | P2RX3ADORA3P2RY12CA5AP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505796-B2 | Phosphorylated A2A receptor agonists | CROZET MEDICAL GMBH (DE) | 2016-11-29 | — | — | US | claimed |
| US-20100048501-A1 | Phosphorylated A2A Receptor Agonists | HEINRICH-HEINE-UNIVERSITAT DUSSELDORF (DE) | 2010-02-25 | — | — | US | claimed |
| EP-2021350-A1 | PHOSPHORYLATED A2A RECEPTOR AGONISTS | Schrader, Jürgen (DE) | 2009-02-11 | — | — | EP | claimed |
| WO-2007107598-A1 | PHOSPHORYLATED A2A RECEPTOR AGONISTS | HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF (DE) | 2007-09-27 | — | — | WO | claimed |
| EP-2021350-B1 | PHOSPHORYLATED A2A RECEPTOR AGONISTS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2016-12-21 | — | — | EP | disclosed |
| US-9505796-B2 | Phosphorylated A2A receptor agonists | CROZET MEDICAL GMBH (DE) | 2016-11-29 | — | — | US | disclosed |
| US-9505796-B2 | Phosphorylated A2A receptor agonists | CROZET MEDICAL GMBH (DE) | 2016-11-29 | — | — | US | disclosed |
| US-9505796-B2 | Phosphorylated A2A receptor agonists | CROZET MEDICAL GMBH (DE) | 2016-11-29 | — | — | US | disclosed |
| US-20140288019-A1 | Phosphorylated A2A Receptor Agonists | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20140288019-A1 | Phosphorylated A2A Receptor Agonists | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20140288019-A1 | Phosphorylated A2A Receptor Agonists | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20100048501-A1 | Phosphorylated A2A Receptor Agonists | HEINRICH-HEINE-UNIVERSITAT DUSSELDORF (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048501-A1 | Phosphorylated A2A Receptor Agonists | HEINRICH-HEINE-UNIVERSITAT DUSSELDORF (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048501-A1 | Phosphorylated A2A Receptor Agonists | HEINRICH-HEINE-UNIVERSITAT DUSSELDORF (DE) | 2010-02-25 | — | — | US | disclosed |
| EP-2021350-A1 | PHOSPHORYLATED A2A RECEPTOR AGONISTS | Schrader, Jürgen (DE) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007107598-A1 | PHOSPHORYLATED A2A RECEPTOR AGONISTS | HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF (DE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048501-A1 | Phosphorylated A2A Receptor Agonists | ADORA2A, ADORA2B, ADORA3 | P2RX3 9/4885ADORA3 3/4885ADORA1 4/4885 |
| US-20140288019-A1 | Phosphorylated A2A Receptor Agonists | ADORA2A, ADORA2B, ADORA3 | P2RX3 9/4885ADORA3 3/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.